Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

CD3⁺cell dose is an independent risk factor for grade II–IV aGVHD following cord blood transplantation in children with aplastic anemia

View Full Paper
Ask AI
Bookmark
Share

Authors

XCXingyu CaoYLYue LuDLDeyan Liu

Discussion

Loading...

Member takes

Overview

Retrospective analysis identifies CD3+ and CD34+ cell doses impacting aGVHD and viral complications in pediatric aplastic anemia.

Key Points

  • A lower CD3+ cell dose significantly reduces the risk of grade II–IV aGVHD, providing important implications for transplantation outcomes.
  • The 5-year overall survival rate reached 83.6%, indicating favorable long-term outcomes following cord blood transplantation in children.
  • Clinical outcomes show a robust correlation between CD34+ doses and reduced incidence of CMV viremia, emphasizing the prognostic value of cell doses.
  • Results highlight the importance of anti-thymocyte globulin in influencing aGVHD risk and underscore the need for tailored therapies for pediatric patients.

Cite This Study

Cao et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d408https://doi.org/10.1182/blood-2025-7752
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1No reduction in gvhd risk for aplastic anemia patients to combined third-party unrelated cord blood in haploidentical hematopoietic stem cells transplantation2025
  2. 2Impact CD34+ cell doses and allograft composition on acute graft-versus-host disease: A single-center prospective cohort study2025
  3. 3Exploring the efficacy and safety of low-dose ATG combined with fractionated low-dose ptcy in preventing gvhd after allogeneic hematopoietic stem cell transplantation2025 · 1 citations
  4. 4Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.2025
  5. 5Avoidance of ATG improves outcomes in double-cord blood transplantation for hematological malignancies2025